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The generation of human embryonic stem cell banking networks has ensured that well-characterized and
quality controlled stem cell lines are broadly accessible to researchers worldwide. Here, we provide recom-
mendations for engaging these established networks in efforts to build similar resources for the distribution
and collection of induced pluripotent stem cells.Introduction
Sharing quality controlled research mate-
rials is a vital component to ensure that
work from different laboratories can
be replicated. However, this important
element in assuring scientific repro-
ducibility could prove challenging for
research conducted with human induced
pluripotent stem cell (hiPSC) lines. The
principle of sharing quality controlled
research materials has been promoted in
the human embryonic stem cell (hESC)
field through government and private
support of central resource centers
to make the lines available to re-
searchers (Luong et al., 2011). It is now a
research-economics imperative that the
hard-won experience achieved in deliv-
ering hESC lines for research should be
utilized in current strategic plans to
create large numbers of hiPSC lines
for research and drug discovery. In this
Forum, we recommend approaches for
utilizing the knowledge of the existing,
well-established hESC banks and
their experience in standardization to
promote consistent and robust quality
control in hiPSC resource centers.
Furthermore, we caution that failure to
capitalize on such knowledge would be
an inefficient use of the public and private
investments now being made in hiPSC
banking.
In spite of the many stem cell scientists
and funding bodies who acknowledge
the value of central quality controlled
systems (Hinxton Accord, 2010), there
has traditionally been little real academicunderstanding or government support
for the substantial and sustained commit-
ment of resources necessary to operate
open service collections in the longer
term. In the case of producing and main-
taining banks for hESC and hiPSC lines,
the work requires the highest level of
competency in cell line production and
handling, underpinned by specialized
infrastructure and quality control for the
maintenance and provision of large cell
stocks for distribution to the international
community. Consequently, greater effort
needs to be directed toward developing
global awareness and support and deliv-
ering adequate and suitable resources
for stem cell banking of hiPSC lines.
Hopefully, such criteria will be addressed
in new initiatives such as CCRM (http://
ccrm.ca/), CIRM (http://www.coriell.org/
media-center/coriell-in-the-news/coriell-
awarded-10mm-for-induced-pluripotent-
stem-cell-program), HiPSCi (http://www.
hipsci.org), and StemBANCC (http://
www.stembancc.org/). Now more than
ever, with the new wave of interest arising
from the discovery of hiPSCs, there is a
risk of developing inadequate programs
of cell line provision should such efforts
fail to build on 20 years of experience in
ESC resource management.
Since 2007, the International Stem Cell
Forum (ISCF), a consortium of more than
20 stem cell research funding bodies
(e.g., NIH, MRC, and NHMRC) from
more than 20 countries, has supported a
program proposed by the UK Stem Cell
Bank to coordinate existing and devel-Cell Stem Cell 1oping stem cell banks, regulators, and
scientists to deliver consensus opinions
on best practices in the management
and distribution of stem cell lines. This
activity, called the International Stem
Cell Banking Initiative (ISCBI; http://
www.stem-cell-forum.net/ISCF/initiatives/
international-stem-cell-banking-initiative/
and Crook et al., 2010), has also provided
a dynamic standards-setting group,
engaging with bodies such as the USFDA,
the WHO, the ISCF Ethics Working Party,
the International Society for Stem Cell
Research (ISSCR), and the International
Society for Cell Therapy (ISCT). The ISCBI
members have published principles of
best practice for supply of hPSC lines to
researchers (Andrews et al., 2009) and
represent an established network of
stem cell providers that provide an
expanded support system to assist new
resource centers worldwide. In particular,
we believe the ISCBI community could
help to avoid the significant and serious
risk of wasting substantial time, effort,
and investment that would occur if
inexperienced groups start out to meet
the challenging demands of delivering
hiPSC lines for research.
We would council that our recommen-
dations do not necessarily mean that the
whole field needs to be slowed down to
wait for extensive characterization and
lengthy cell expansion procedures. Our
proposal would, however, require coordi-
nation among resource centers experi-
enced in international supply of stem cell
lines, researchers, and funders to deliver3, October 3, 2013 ª2013 Elsevier Inc. 385
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to providing research and industry with
access to suitably qualified, traceable,
and reliable supplies of hiPSC lines within
acceptable time frames. It will be impor-
tant for resource centers or stem cell
banks to avoid adopting a simple ‘‘stamp
collecting’’ approach (i.e., the temptation
to focus on numbers of cell lines), and
this will mean close coordination with
the centers researching particular disease
groups to ensure efforts are focused on
making the most relevant and effective
hiPSC lines available to the broader
research community.
It is clear that hiPSC lines contain
genetic and epigenetic variations (Liang
and Zhang, 2013), both of which could
impact the value of any data from such
lines. While hiPSCs and hESCs appear
to have broadly consistent characteris-
tics, they may also show subtle adapta-
tions to cell culture in vitro (Yamanaka
et al., 2012; Amps et al., 2011). Clearly,
this variation in genetic and phenotypic
integrity means that, in order to be
suitable for research, stem cell lines
require careful quality control, and
characterization of multiple lines for each
representative genotype may be needed.
Setting Standards
The fundamental principles for interna-
tional banking and supply of pluripotent
stem cells described by ISCBI (Andrews
et al., 2009) include several crucial
features. First among these is the need
for appropriate governance in procuring
cell lines through the application of
rigorous selection criteria to ensure that
resources are committed only to cells of
suitable and documented scientific
quality that comply with ethical norms
for consent and donation of human tis-
sues. Second, there is a fundamental
requirement for traceability and good
scientific documentation in the banking
process to provide clarity on how cells
have been prepared and to allow any
errors that do occur to be resolved. Under
this framework secure and protected
archive or master bank stocks must then
be established that provide low-passage
reference cells for future replacement
and supply. These banks then need
appropriate quality control to prevent the
transfer of cell lines that are misidentified
or suffer the deleterious biological effects
of microbial contaminants. They also386 Cell Stem Cell 13, October 3, 2013 ª201require controlled and well-documented
storage to assure fast and reliable supply
from frozen stocks. Finally, these stocks
must be released under appropriate
transfer agreements that do not apply
serious constraints on research or seek
to establish ownership of discoveries
from that research.
Ongoing commitment to large-scale
banking, storage, quality control, and
cataloguing requires significant financial
support. Priority should be given to
banking cells that will find the greatest
demand in the community. Such organi-
zation will require the establishment of
procedures that will enable precious
banking resources to be focused on
biologically competent hiPSC lines from
donors with disease types most relevant
to research efforts and to avoid cell lines
that would invoke problematic intellectual
property rights. It is also important to un-
derstand that simply generating a single
stock of cells of each line will not deliver
a long-term supply. This will require plans
for establishment of master and distribu-
tion banks (to assure long-term provision
of important cell lines at the same culture
passage level), procedures to reject
batches that do not meet scientific quality
criteria (e.g., due to ‘‘spontaneous’’
differentiation), and plans for rebanking
popular stocks.
Delivering Quality Stem Cell
Resources
To fully support new hiPSC banking initia-
tives, it will be crucial to identify centers
that operate to a suitable standard and
are able to form a sufficient distribution
network to coordinate and support
banking activities. While setting stan-
dards is valuable and important, the real
‘‘litmus’’ test of a standard is to demon-
strate its implementation. Accordingly,
the ISCBI group described above has
considered how to ensure that individual
banks are all working to the standard
established in 2009 (Andrews et al.,
2009) by developing an evaluation proce-
dure (Table S1, available online) that could
be used to help new distribution centers
establish and implement appropriate
systems and methods. This system
requires each center to describe exactly
how they meet the established standard,
rather than just ticking a box thatmay indi-
cate an aspiration to good standards
rather than a commitment to meeting3 Elsevier Inc.them. In particular, the self-evaluation
questionnaire shown in Table S1 is
intended to draw out specific crucial infor-
mation on how each bank is operated.
Section 1 in the Table challenges the
robustness of a bank’s procedures to pre-
vent cell lines from being distributed
without appropriate informed consent.
An important criterion is that it should be
clear that the donor understood that cell
lines may be derived from his/her tissue
that could be used in the performance
of broad-ranging research, including
genetic testing. In Section 2 on procure-
ment, banking, and release of cell lines,
it is especially important for banks to iden-
tify how to ensure consistent banking and
testing procedures. Responses to micro-
biological risk assessment and testing
procedures (Section 3) are meant to indi-
cate that any evident serious infectious
hazard represented by a cell line due to
the patient of origin or reagents used in
its isolation and culture is satisfactorily
addressed by use of screening tests
of appropriate sensitivity. In addition, a
bank should be able to demonstrate that
it has been adequately diligent to prevent
exposure of users of cell lines to serious
human pathogens and to inform users of
residual risks that cannot be covered by
the bank. The ISCBI guidance also
addresses the important issue of charac-
terization, and the evaluation process
seeks to demonstrate how the most
fundamental generic features of human
pluripotent stem cells are checked and re-
ported to users. Sections 5 and 6 require
each bank to state how the minimum sci-
entific and ethical standards for cells they
release to researchers are sustained, the
methods used to ship cells, and how intel-
lectual property in the cells is managed.
Importantly, the ISCBI standard is not
intended to create an elite group of domi-
nant banking centers but to focus the
attention of all those aspiring to provide
stem cells to the community on the key
issues and help them to address elements
that are not fully met in their own activity.
Clearly, established expert centers, in-
cluding those contributing to the ISCBI
network, will have an important role to
play by providing advice and training for
those new to stem cell distribution.
Of course coordination alone will not
achieve what is needed for hiPSC
banking. There is an urgent need to estab-
lish routine screening methods that will
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on self-renewal, potential pluripotency,
quality of reprogramming, cell line iden-
tity, and infectious agents. This will be
vital to avoid squandering resources on
unsuitable cell lines and submission of
publications that are flawed due to
fundamental shortcomings in cell line
characterization.
There is also a need for mechanization
and automation in the banking process
to provide turn-key solutions, such as
automated cell aliquotting machines,
where possible to expedite and streamline
banking procedures. In addition, it will be
vital to apply more effort to educate and
encourage the research community to
implement best practices for cell culture,
preservation, and quality control (Coecke
et al., 2005). In particular, this education
in standardization will need to include
new graduates, researchers intending to
use cell culture for the first time, and senior
staff for whom culture of hiPSC lines is a
new technology under their supervision.
The primary responsibility lies with those
overseeing the development of the field,
including funders, scientific societies,
and research organizations. In addition,
the stem cell banks can provide valuable
training opportunities based on experi-
ence of culturing many different cell lines.
Finally, although potentially conten-
tious, perhaps the best way to achieve
universal compliance with good practice
would be for granting agencies and
journals to require researchers to use
agreed-upon standards in order to access
funding or publish (Andrews et al., 2009;
Coecke et al., 2005). To this end, major
public funding agencies such as the NIH
in the United States, MRC in the UK,
NHMRC in Australia, NMRC in Singapore,
CIHR in Canada, and JST in Japan are
uniquely positioned to lead. NIH has taken
the lead in one aspect of good cell culture
practice by issuing a notice (NOT-OD-08-
017) encouraging cell line authentication,
although this is not currently required to
receive an NIH grant.
The Consequences of Failure
Failure to address this call for a
coordinated effort on delivery of hiPSCs
to the community is likely to have serious
consequences. Certainly, the circulation
of poor-quality, misidentified, or myco-
plasma-infected cell lines would sustain
an unacceptable waste of resources andpublication of misleading information.
Shockingly, in other fields, such as cancer
research, cross-contamination events
alone are estimated to have cost millions
of dollars of misspent research money
(NIH Catalyst, 2008). In addition, the
wide variation in experience in cell culture
across the research community has led to
the circulation of cross-contaminated or
misidentified (switched) cell lines, culmi-
nating in the publication of misleading
data (e.g., MacLeod et al., 1999; Podolac,
2010). While NIH and other funders have
attempted to address the issue of cell
line cross-contamination (see above),
more effort is needed to ensure the quality
of cells used in research.
Today there are very strong demands
and pressures for researchers to generate
vast numbers of hiPSC lines. Many of
those wishing to respond to this demand
will experience a steep learning curve,
and if not supported appropriately, this
challenge could create a legacy of large
numbers of unqualified cell lines, signifi-
cant numbers of which could even turn
out not to have pluripotent potential. It
could take decades to resolve any
ongoing issues from published work on
misidentified or contaminated lines alone.
Just as important, there could be a loss of
public and political support if funding is
deemed to have been wasted. A recent
meeting of ISCBI and stem cell biologists
from Europe, Japan, and the US (coordi-
nated by the UKSCB and University of
Massachusetts Stem Cell Bank with
funding from the British Consulate in
Boston) considered the properties of
hiPSC lines and the requirements for
creating hiPSC cell banks. An outcome
of the meeting (see ISCBI weblink above)
was for ISCBI to consider collating scien-
tific standards for defining and testing
hiPSCs and assemble them into a
consensus that adds to the guidance
on best practices already published
(Andrews et al., 2009). (Footnote: sadly,
the University of Massachusetts Stem
Cell Bank was closed in December 2012.)
Conclusion
Culture of pluripotent stem cell lines incor-
porates a range of challenging skills that
should not be underestimated. We need
to ensure sufficient care is applied in the
delivery of these important and sensitive
research reagents to assist researchers
in providing data that most closely mimicsCell Stem Cell 1the in vivo situation. This requirement has
never been more evident than in the case
of research using hiPSC lines, where there
is the potential to create powerful in vitro
models of human tissue and disease,
but also where adoption of suboptimal
cell culture and banking practices could
permanently alter or eliminate their key
properties. While it is important to strive
to realize the exciting benefits of access
to large numbers of hiPSC lines from
both ethnically diverse and disease-
affected backgrounds, the core scientific
quality of the cells is paramount. Failure
to address this important issue could
result in a potentially expensive disaster
in the field with a legacy that would endure
for decades, as witnessed in the case of
cross-contaminated cancer cell lines. In
the absence of mandatory rules for cell
line authentication, the cancer cell prob-
lem has now been the subject of con-
cerned scientific commentaries for more
than 30 years, with the distribution of
contaminated cell lines and likely publica-
tion of corrupted research continuing. The
experienced banking centers that have
coordinated to develop harmonized best
practices for researching stem cells will
probably be the only beneficiaries from
this confusion, as they have focused on
careful curation and quality control of
pristine early passage material that will
be needed to resolve problems of cell
authenticity in the future. Nevertheless,
we urge the scientific community and their
funders to consider the dangers of pursu-
ing massive hiPSC generation programs
without full consideration and consulta-
tion to (1) ensure that the focus is on key
genotypes needed in research and indus-
try, and (2) assure that careful attention to
deliver cells of appropriate ethical prove-
nance and suitable scientific quality is
achieved. The ISCBI participants have
been working hard to coordinate the
efforts of established and developing
stem cell banks and provide a unique
resource of combined expertise and
experience to advise and assist new
hiPSC banking efforts. While there is a
clear need for significant numbers of
hiPSC lines, our priority must be to ensure
a focus on appropriate scientific quality.
SUPPLEMENTAL INFORMATION
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